Babies born to mothers diagnosed with cannabis use disorder are more likely to experience negative health outcomes, such as preterm birth and low birth weight, than babies born to mothers without a cannabis use disorder diagnosis, report UC San Diego researchers.
Since 2016, a federal regulation has allowed nurse practitioners and physician assistants to obtain a waiver to prescribe buprenorphine, a medication used to treat opioid use disorder as a medication assisted treatment.
For patients undergoing spinal surgery, the diagnosis of cannabis use disorder is associated with higher complication rates, including substantially increased risks of stroke and respiratory complications, reports a study in Spine. The journal is published in the Lippincott portfolio by Wolters Kluwer.
A string of opioid trade sites on the dark web have been uncovered by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics.
UC San Diego School of Medicine researchers report that opioid users who participated in a 12-step abstinence program and recently stopped using drugs refused to take home naloxone, even if having it on hand might save lives.
A Penn Medicine new study of how text messaging could inform opioid prescribing practices showed that 60 percent of opioids are left over after orthopaedic and urologic procedures
The Foundation for Opioid Response Efforts (FORE) and the Addiction Policy Forum (APF) are launching a program to assist people with substance use disorder obtain COVID-19 vaccinations.
Topics surrounding asthma and power plant closures, illicit drug use and harm reduction, testing access for homeless, and varied support for pandemic measures will be highlighted in the May 2021 Issue of AJPH.
The Arkansas Society of Anesthesiologists (ARSA) and the American Society of Anesthesiologists (ASA) today applaud bill sponsor Sen. Cecile Bledsoe and the Arkansas Senate Public Health, Labor and Welfare Committee for helping to ensure the safety of patients prescribed opioids. Arkansas State Drug Director Kirk Lane and Jonathan Goree, M.D., a physician anesthesiologist and pain medicine specialist, testified for the bill.
Researchers at Penn Medicine used machine learning-aided analysis to uncover top positive and negative themes in patient Yelp reviews of substance use treatment facilities
The coronavirus pandemic has led to several temporary regulatory relaxations and policy innovations in treatment for opioid use disorder aimed at making it easier for those seeking care to access treatment without risking in-person interactions. The Foundation for Opioid Response Efforts (FORE) today announced it is providing grants totaling $1.3 million to six organizations to assess the impact of these temporary measures and inform future policies to improve access and promote equity for the treatment of opioid use disorder.
The first-wave COVID-19 lockdown in Barcelona, Spain, has been linked to increased drinking among people recovering from alcohol use disorder (AUD), as reported in Alcoholism: Clinical and Experimental Research. Pandemic-associated stress has already been associated with increased drinking in the general population, but few studies have examined the impact among people with a clinical diagnosis of AUD, who may be particularly susceptible to using alcohol as a coping mechanism. Additionally, almost all COVID-19 studies to date have been based on self-reported alcohol use, which does not always provide an accurate measure, particularly among heavy drinkers and those with AUD. In the latest study, researchers used the results of urine alcohol tests to assess changes in alcohol consumption among people with AUD before and after the first-wave lockdown. Although the lockdown in Spain was one of the strictest in the world, with residents allowed to leave homes for basic needs only, alcohol r
Although the prevalence of opioid use among Black people is comparatively low, the rate of opioid deaths has increased the sharpest and fastest among that population in recent years, according to an article in the March/April issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
One of the nation’s largest research projects aimed at measuring the outcomes of medication-assisted recovery (MAR) housing for opioid-use disorder will launch this spring, led by harm reduction specialists at The University of Texas Health Science Center at Houston (UTHealth) in partnership with the Health and Human Services Commission’s Texas Targeted Opioid Response Program (TTOR).
For the first time, an app has been shown to reduce key symptoms of chronic pain. A UNH-led study evaluated the impact of Manage My Pain(MMP), a digital health solution on chronic pain patients.
A new review article published in the March issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) examines the variability that exists in opioid prescribing patterns across the United States for many common orthopaedic procedures. While the Northeast and Midwest were most impacted by the opioid epidemic, the study found that patients in the West and South consistently were given prescriptions at or greater than the national medians. These regional and national variations in opioid prescribing practices can serve as a benchmark for orthopaedic surgeons to help develop guidelines to reduce excess postoperative opioid prescriptions.
In a study at Penn researchers found that Pennsylvania’s financial incentive policy encouraged hospitals to enact rapid changes to support treatment for opioid use disorder for patients visiting the ED, and evaluates the efficacy of the Opioid Hospital Quality Improvement Program.
The University of New Hampshire’s Outdoor Behavioral Healthcare Center will receive $2.97 million in grants to conduct a first-of-its-kind randomized study looking at the effectiveness of outdoor behavioral health (OBH), or wilderness therapy, a prescriptive treatment for teens struggling with depression, anxiety and substance use disorders.
WEST BLOOMFIELD, MI (February 23, 2021)—Henry Ford Maplegrove Center is pleased to announce that it has been designated as a Cigna Center of Excellence for Substance Use. The designation recognizes top performing addiction recovery centers that provide patients with quality care, an exceptional experience and cost efficiency.
DALLAS – Feb. 22, 2021 – Three decades-old antibiotics administered together can block a type of pain triggered by nerve damage in an animal model, UT Southwestern researchers report. The finding, published online today in PNAS, could offer an alternative to opioid-based painkillers, addictive prescription medications that are responsible for an epidemic of abuse in the U.S.
People treated with chronic opioid therapy for pain are more likely to live in socially disadvantaged areas and self-report worse anxiety, depression and pain that interferes in their lives, according to a new study presented this week at the Association of Academic Physiatrists Annual Meeting.
The Data Science for the Public Good program, an Iowa State University project to help Iowa towns harness their data, has led to four offshoot projects to help support community recovery related to economic vulnerability, substance use and general support.
DALLAS – Feb. 5, 2021 – The COVID-19 pandemic is having a detrimental impact on substance use, mental health, and weight-related health behaviors among people with obesity, according to a new study by researchers at UT Southwestern and the UTHealth School of Public Health.
People who take opioid medications for chronic pain may have a hard time finding a new primary care clinic that will take them on as a patient if they need one, according to a new “secret shopper” study of hundreds of clinics across the country.
A coalition of 31 professional and advocacy organizations has released a set of principles aimed at guiding state and local spending of the forthcoming opioid litigation settlement funds.
Patients with substance use disorders (SUDs) being treated for serious medical conditions are more likely to leave the hospital against medical advice (AMA) than those without addiction. A special type of contract with healthcare providers might enable patients to consent in advance to life-saving medical care – even if they later refuse treatment, according to a commentary in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published in the Lippincott portfolio by Wolters Kluwer.
DALLAS – Jan. 13, 2021 – A new treatment that combines two existing medications may provide long-sought relief for many battling debilitating methamphetamine use disorder, according to a study to be published tomorrow in The New England Journal of Medicine.
A new study out of the University of Chicago Medicine following young adult drinkers for 10 years has found that individuals who reported the highest sensitivity to alcohol’s pleasurable and rewarding effects at the start of the trial were more likely to develop an alcohol use disorder (AUD) over the course of the study.
Researchers at Case Western Reserve University find that focusing on diversion—instead of detention—yields positive results for youth with behavioral health issues
Strengthening the Heartland, an SDSU Extension program that provides free seminars to increase awareness and knowledge about opioids among youth and adults in rural South Dakota, will be expanding its programming.
New research suggests that cannabis use by people in care for opioid addiction might improve their treatment outcomes and reduce their risk of being exposed to fentanyl in the contaminated unregulated drug supply.
Researchers at University of California San Diego School of Medicine will expand a statewide program to prevent driving under the influence of alcohol, cannabis and prescription drugs.
A new report from researchers at the Johns Hopkins Bloomberg School of Public Health offers recommendations aimed at federal, state, and local policymakers to address the opioid epidemic during the pandemic.
Having hope for the future could protect people from risky behaviours such as drinking and gambling - according to new research from the University of East Anglia.
Study finds no decrease in prescription fills or clinician visits in the first three months of the COVID-19 pandemic for patients recently receiving opioid use disorder therapy.
On the flip side, the study found that during this period fewer people started new treatment for opioid use disorder and fewer urine tests were given across both new and established patients.
Findings identify strengths and weaknesses in telemedicine’s role for opioid use disorder during shutdowns and can inform strategies for improvement.
A world-first study by the University of South Australia has found that survivors of child abuse are more than twice as likely to die young than children who have never come to the attention of child protection services.
The opioid epidemic has only gotten worse since the advent of COVID-19, with some areas in the U.S. reporting a 50% increase in drug overdoses due to the pandemic. With no end in sight to this public health crisis, scientific sessions during the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo will highlight the integral role of clinical laboratories in efforts to manage it, as well as the latest drug tests needed to do so.
Cocaine continues to be one of the most commonly abused illicit drugs in the United States. Pre-clinical literature suggests that targeting glucagon-like peptide-1 receptors (GLP-1Rs) in the brain may represent a novel approach to treating cocaine use disorder. Specifically, GLP-1R agonists, which are FDA-approved for treating diabetes and obesity, have been shown to reduce voluntary drug taking and seeking in preclinical models of cocaine used disorder. However, the exact neural circuits and cell types that mediate the suppressive effects of GLP-1R agonists on cocaine-seeking behavior are mostly unknown.
Research from Saint Louis University finds that among patients at risk for opioid misuse, the odds of receiving a schedule II opioid for non-cancer pain were similar to those not at risk, despite new prescribing guidelines from the Centers for Disease Control (CDC).